Clinical trials: Hepato-cellular Carcinoma
Decompensated Liver Cirrhosis, Primary Biliary Cholangitis
LEOPARD Training and Validation Data Collection Study
Intro: The present clinical research protocol is part of the LEOPARD European project (Grant n° 101080964 Horizon Europe) which aims to design and validate new predictive models of mortality among liver transplantation (LT)…
- Conditions
- Decompensated Liver Cirrhosis, Primary Biliary Cholangitis, Primary Sclerosing Cholangitis, Hepato-cellular Carcinoma
- Trial name
- LEOPARD TVDCS (NCT06675604)
- Where
- 53 sites in Austria, Belgium and 5 more
- Volunteers
- 4,500 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Decompensated Liver Cirrhosis, Primary Biliary Cholangitis
LEOPARD Prospective Validation Cohort 1
Intro: The present clinical research protocol is part of the LEOPARD European project (Grant n° 101080964 Horizon Europe) which aims to design and validate new predictive models of mortality among liver transplantation (LT)…
- Conditions
- Decompensated Liver Cirrhosis, Primary Biliary Cholangitis, Primary Sclerosing Cholangitis, Hepato-cellular Carcinoma
- Trial name
- LEOPARD PVC1 (NCT06723275)
- Testing
- Standardized assessments, guided tumor biopsy and biobanking, Standardized assessments and biobanking
- Where
- 8 sites in Belgium, France and 3 more
- Volunteers
- 630 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Hepato Cellular Carcinoma
Ebastine for Adjuvant Treatment of Tumor Budding-Positive Liver Cancer After Surgery
This study evaluates ebastine, an FAK (focal adhesion kinase) inhibitor, as adjuvant therapy to reduce the risk of recurrence in patients with hepatocellular carcinoma (HCC) who have undergone curative hepatectomy and whose…
- Trial name
- NCT07734766
- Testing
- Ebastine
- Volunteers
- 45 people
- Sponsor
- Second Affiliated Hospital of Xi'an Jiaotong University
Hepato Cellular Carcinoma (HCC), Sedation and Analgesia
The Impact of Anaesthesia and Sedation on Inflammation and NETosis in Hepatocellular Carcinoma Ablation
According to recent literature, liver disease causes approximately 2 million deaths annually; 1 million are attributed to the complications of cirrhosis, while the remaining deaths are caused by hepatocellular carcinoma (HCC).
- Conditions
- Hepato Cellular Carcinoma (HCC), Sedation and Analgesia, Ablation Techniques
- Trial name
- NCT07657897
- Testing
- Sedation using combination of Propofol and Fentanyl., Sedation using combination of Propofol and Fentanyl and lidocaine
- Where
- Romania
- Volunteers
- 100 people
- Sponsor
- Iuliu Hatieganu University of Medicine and Pharmacy
Hepato Cellular Carcinoma, Intrahepatic Bile Duct Carcinoma
Inter-Individual Tumor Heterogeneity on 3D-MRE for Predicting Response to Conversion Therapy in Liver Cancer
How to predict which patients with initially unresectable liver cancer are more likely to respond to conversion therapy remains an important unresolved problem in guiding treatment strategy and surgical timing.
- Conditions
- Hepato Cellular Carcinoma, Intrahepatic Bile Duct Carcinoma, Metastatic Hepatocellular Carcinoma
- Trial name
- NCT07716345
- Testing
- Three-Dimensional Magnetic Resonance Elastography
- Volunteers
- 100 people
- Sponsor
- Second Affiliated Hospital of Xi'an Jiaotong University
Hepato Cellular Carcinoma (HCC), Intrahepatic Cholangiocarcinoma
Outpatient Versus Inpatient Care Pathway for Intra-arterial Treatment of Primary Liver Cancer (CHOC)
Randomized multicentre trial comparing two care organisations (ambulatory vs conventional inpatient) for patients undergoing transarterial chemoembolization (TACE) or radioembolization (TARE) for primary liver cancer (Hepato…
- Trial name
- CHOC (NCT06990659)
- Testing
- Ambulatory care, Conventional inpatient care
- Where
- 19 sites in France
- Volunteers
- 206 people
- Sponsor
- University Hospital, Angers
Hepato Cellular Carcinoma, Intrahepatic Bile Duct Carcinoma
Peritumoral MRE Stiffness for Predicting Resection Margin Status and Recurrence in Liver Cancer
Microscopic residual tumor at the resection margin is a critical risk factor for recurrence in patients undergoing hepatectomy for liver cancer, yet current detection relies solely on postoperative pathological examination of the…
- Conditions
- Hepato Cellular Carcinoma, Intrahepatic Bile Duct Carcinoma, Metastatic Hepatocellular Carcinoma
- Trial name
- NCT07704216
- Testing
- Three-Dimensional Magnetic Resonance Elastography
- Volunteers
- 150 people
- Sponsor
- Second Affiliated Hospital of Xi'an Jiaotong University
Hepato-cellular Carcinoma, Neutrophil Extracellular Trap Formation
Evaluation Of The Influence Of Anesthetic Interventions On The Evolution Of Hepatic Neoplastic Processes
Evaluation Of The Influence Of Anesthetic Interventions On The Evolution Of Hepatic Neoplastic Processes The goal of this clinical trial is to evaluate of the involvement of Neutrophil extracellular traps in the evolution of…
- Conditions
- Hepato-cellular Carcinoma, Neutrophil Extracellular Trap Formation, Anesthesia, Lidocaine Infusion
- Trial name
- NCT07207304
- Testing
- Anesthesia, Anesthesia induction with TCI, sevoflurane anesthesia
- Where
- Romania
- Volunteers
- 153 people
- Sponsor
- Iuliu Hatieganu University of Medicine and Pharmacy
Hepato Cellular Carcinoma
Kinectics of Distribution of Doxorubicin-Lipiodol Emulsion in c-TACE
Conventional transarterial chemoembolization with Doxorubicin (c-TACE) is the gold standard treatment for Hepato Cellular Carcinoma (HCC) stage B (BCLC) / stages A and B (Child-Pugh).
- Trial name
- CineDoxo (NCT03706157)
- Testing
- Super selective transarterial chemoembolization of CHC, with doxorubicin reconstituted in 5cc iso-osmolar ionic iodinated contrast media, Super selective transarterial chemoembolization of CHC, with doxorubicin reconstituted in 5cc normal saline
- Where
- France
- Volunteers
- 10 people
- Sponsor
- University Hospital, Strasbourg, France
Hepato Cellular Carcinoma (HCC)
Fecal Microbiota Transplantation to RESCUE Patients With Unresectable Hcc Progressors to First Line Therapy With AtezolizUmaB and Bevacizumab
The purpose of this study is to evaluate whether fecal microbiota transplantation (FMT), when administered in combination with atezolizumab and bevacizumab, can improve treatment response in participants with hepatocellular…
- Trial name
- NCT07276100
- Testing
- Fecal microbiota transplantation (FMT), Atezolizumab & Bevacizumab
- Where
- Italy
- Volunteers
- 15 people
- Sponsor
- IRCCS Azienda Ospedaliero-Universitaria di Bologna
Hepato Cellular Carcinoma (HCC), Hand Foot Skin Syndrome
SHIELD: Sorafenib Hand-foot Syndrome Inhibition With Pre-Emptive Local Delivery of Topical Indomethacin
SHIELD is a single-center, open-label, single-arm prospective study designed to evaluate whether pre-emptive topical indomethacin can reduce sorafenib-associated hand-foot syndrome (HFS) in patients with advanced hepatocellular…
- Trial name
- NCT07560566
- Testing
- Topical Indomethacin
- Where
- Taiwan
- Volunteers
- 39 people
- Sponsor
- National Taiwan University Hospital
Hepato Cellular Carcinoma, Cirrhosis
PSYLIVER-PILOTE: Involvement of the Autonomic Nervous System in Hepatocellular Carcinoma (HCC)
Chronic liver diseases affect 1.5 billion people worldwide and can lead to cirrhosis and hepatocellular carcinoma (HCC), which ranks as the third leading cause of cancer-related mortality globally.
- Conditions
- Hepato Cellular Carcinoma, Cirrhosis, Autonomic Nervous System, Central Nervous System
- Trial name
- PSYLIVER-PILOT (NCT07393074)
- Testing
- Measurements of autonomic nervous system (ANS) activity at rest and during sensory stimulation., Self-administered questionnaires to assess psycho-behavioral traits, Analysis of nocturnal cardiac activity (at home): electrocardiographic (ECG) recording of heart activity during one night.
- Where
- France
- Volunteers
- 100 people
- Sponsor
- Hospices Civils de Lyon
Hepato Cellular Carcinoma (HCC)
A Platform Trial for Personalized and Adaptive Therapies in Hepatocellular Carcinoma
This is a phase II, multi-arm, Bayesian adaptive platform trial designed to efficiently evaluate novel therapies for advanced hepatocellular carcinoma (HCC) after first-line treatment failure.
- Trial name
- HCC-SIGHT (NCT07328009)
- Testing
- Lenvatinib, Regorafenib (BAY 73-4506), Tislelizumab+TKI
- Where
- China
- Volunteers
- 350 people
- Sponsor
- Fudan University
Hepato Cellular Carcinoma (HCC)
Becotatug Vedotin (MRG003) in Previously Treated Advanced Hepatocellular Carcinoma
This study will evaluate the efficacy and safety of Becotatug vedotin, MRG003, in previously treated advanced hepatocellular carcinoma (HCC).
- Trial name
- NCT07536789
- Testing
- MRG003
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Fudan University
Hepato Cellular Carcinoma (HCC)
TACE or Ablation Combined With Sintilimab and Ipilimumab N01 as Neoadjuvant Therapy for Resectable Hepatocellular Carcinoma With Intermediate-High Recurrence Risk
Hepatocellular carcinoma (HCC) is one of the leading causes of cancer-related mortality worldwide. The recurrence rate after curative resection for early-stage HCC remains extremely high, with 2-year and 5-year recurrence rates…
- Trial name
- ACTION-001 (NCT07487662)
- Testing
- sintilimab, ipilimumab N01, Lenvatinib
- Volunteers
- 105 people
- Sponsor
- Sun Yat-sen University
Hepato Cellular Carcinoma
IIT2025-03-YANG-LIFT-HCC
The investigators are doing this study to learn if a combination of immunotherapy and a liver-directed tumor procedure can safely and effectively shrink or control liver cancer (hepatocellular carcinoma, HCC).
- Trial name
- NCT07489976
- Testing
- STRIDE Regimen (Tremelimumab 300 mg AND Durvalumab 1500 mg) combined with LRT (TACE, TARE, or RFA)
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- Ju Dong Yang
Hepato Cellular Carcinoma (HCC), Renal Cell Cancer
Phase 2 Study of WGI-0301 Plus Nivolumab in Patients With HCC and RCC
This is a Phase II study being done at several hospitals without using a placebo. It will look at how safe and tolerable the drug WGI-0301 is when given together with nivolumab, how the body processes and responds to WGI-0301…
- Trial name
- NCT07494435
- Testing
- WGI-0301, Nivolumab (240 mg)
- Where
- China
- Volunteers
- 230 people
- Sponsor
- Zhejiang Haichang Biotech Co., Ltd.
Hepato Cellular Carcinoma (HCC), Immunotherapy
Effects of Neoadjuvant Immunotherapy on Anti-tumour Immunity in Hepatocellular Carcinoma Patients Undergoing Liver Resection
Our study aims to evaluate the benefit of the administration of immunotherapy (atezolizumab), in patients with hepatocellular carcinoma (HCC), prior surgical resection of the tumor.
- Trial name
- NCT07461675
- Testing
- Atezolizumab
- Where
- Switzerland
- Volunteers
- 30 people
- Sponsor
- University of Geneva, Switzerland
Hepato Cellular Carcinoma (HCC)
Transarterial Chemoembolization (TACE) Plus ABCB1 Inhibition Versus TACE Alone in Patients With Hepatocellular Carcinoma
IMPACT-TACE is an investigator-initiated, prospective, multicenter, randomized, double-blinded, interventional trial to test the hypothesis that the simultaneous application of doxorubicin with the ABCB1 inhibitor nicardipine…
- Trial name
- IMPACT-TACE (NCT07302919)
- Testing
- DEB-DoxNic-TACE, current standard of care
- Where
- 3 sites in Switzerland
- Volunteers
- 152 people
- Sponsor
- University Hospital, Basel, Switzerland
Hepato Cellular Carcinoma (HCC)
BC3402 w/ Tremelimumab + Durvalumab (STRIDE) in Hepatocellular Carcinoma
The purpose of this study is to test the safety and efficacy of an investigational (experimental) product called BC3402. This product is considered experimental because it is not approved by the U.S.
- Trial name
- NCT06608940
- Testing
- BC3402, Durvalumab, Tremelimumab
- Where
- United States
- Sponsor
- Case Comprehensive Cancer Center